As shown in this study, Olaparib has a high response rate of 87.5% (14 out of 16) among patients who have homozygous deletions and/or deleterious mutations in DNA repair genes. Given the high specificity of this PARP inhibitor for this subset of patients with DNA repair defects, as detected by NGS, could Olaparib become the front line treatment and perhaps replace other therapies such as androgen deprivation therapy, docetaxel, etc. to avoid chemical/surgical castration in the near future? With that said, NGS would need to be adopted as a routine clinical diagnostic test to rationalize the use of PARP inhibitor ahead of other traditional therapies.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.